Literature DB >> 31447319

Human CD141+ dendritic cells generated from adult peripheral blood monocytes.

Soo Ji Kim1, Girak Kim2, Narae Kim2, Hyuk Chu3, Byung-Chul Park4, Jae Seung Yang5, Seung Hyun Han6, Cheol-Heui Yun7.   

Abstract

Human CD141+ dendritic cells (DCs), specialized for cross-presentation, have been extensively studied in the development of DC-based therapy against cancer. A series of attempts was made to generate CD141+ DCs from cord blood CD34+ hematopoietic progenitors to overcome the practical limitation of in vivo rareness. In the present study, we identified a culture system that generates high CD141+ DCs. After culture of CD14+ monocytes in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 8 days, CD141 was detected on cells that adhered to the bottom of the culture plate. The attached cells exhibited typical features of immature monocyte-derived DCs (moDCs), except for higher CD86 expression, more dendrites and higher granularity compared with those that did not attach. With 3 additional days of culture, increased CD141 expression on the cells was retained along with adhesion ability and partial expression of CLEC9A, a c-type lectin receptor. Furthermore, the cells exhibited effective uptake of dead cells. Interestingly, the attached moDCs differently responded to polyinosinic:polycytidylic acid (poly I:C) stimulation as well as a mixed lymphocyte reaction. Collectively, our findings show that human CD141+ DCs can be sufficiently generated from peripheral blood CD14+ monocytes, potentiating further investigation into generation of higher yields of cross-priming human DCs in vitro.
Copyright © 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD141(+); adhesion; dead cell uptake; granulocyte macrophage colony-stimulating factor/interleukin-4–driven culture system; monocyte-derived dendritic cells

Mesh:

Substances:

Year:  2019        PMID: 31447319     DOI: 10.1016/j.jcyt.2019.07.007

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

1.  Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study.

Authors:  J-F Peña-Cardelles; J-J Pozo-Kreilinger; G Roncador; J Esteban-Hernández; J-L Cebrián-Carretero; J-E Moro-Rodríguez
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-09-01

Review 2.  Epigenetics of Dendritic Cells in Tumor Immunology.

Authors:  Gerard Godoy-Tena; Esteban Ballestar
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

3.  The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.

Authors:  Silvano Sozzani; Daniela Bosisio; Hoang Oanh Nguyen; Valentina Salvi; Laura Tiberio; Fabrizio Facchinetti; Mirco Govoni; Gino Villetti; Maurizio Civelli; Ilaria Barbazza; Carolina Gaudenzi; Mauro Passari; Tiziana Schioppa; Francesca Sozio; Annalisa Del Prete
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440

4.  Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.

Authors:  Megan S Molina; Emely A Hoffman; Jessica Stokes; Nicole Kummet; Kyle A Smith; Forrest Baker; Tiffany M Zúñiga; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

5.  AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma.

Authors:  Keitaro Fukuda; Ken Okamura; Rebecca L Riding; Xueli Fan; Khashayar Afshari; Nazgol-Sadat Haddadi; Sean M McCauley; Mehmet H Guney; Jeremy Luban; Takeru Funakoshi; Tomonori Yaguchi; Yutaka Kawakami; Anastasia Khvorova; Katherine A Fitzgerald; John E Harris
Journal:  J Exp Med       Date:  2021-07-29       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.